BioCentury
ARTICLE | Company News

FDA approves Amgen's Corlanor for heart failure

April 16, 2015 2:23 AM UTC

FDA granted marketing approval for Corlanor ivabradine from Amgen Inc. (NASDAQ:AMGN) to treat chronic heart failure. The selective If channel inhibitor will launch within one week at a wholesale acquisition price of $375 per month. Corlanor had Fast Track designation and was under Priority Review.

Corlanor is indicated for patients with stable, symptomatic chronic heart failure with a resting heart rate of at least 70 beats per minute and who are on maximally tolerated doses of beta blockers or have a contraindication to beta blocker use. ...